B. Riley Financial Issues Pessimistic Forecast for Immunic (NASDAQ:IMUX) Stock Price

Immunic (NASDAQ:IMUX) had its target price cut by equities research analysts at B. Riley Financial from $40.00 to $27.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. B. Riley Financial’s target price would indicate a potential upside of 105.64% from the stock’s previous close.

Several other analysts also recently issued reports on the company. upgraded Immunic to a “strong-buy” rating in a report on Tuesday, February 3rd. Wolfe Research assumed coverage on Immunic in a research report on Friday. They issued an “outperform” rating for the company. Stifel Nicolaus set a $25.00 target price on Immunic and gave the company a “buy” rating in a research note on Thursday, April 16th. Roth Mkm reiterated a “buy” rating and set a $19.00 target price on shares of Immunic in a report on Thursday, May 14th. Finally, Wall Street Zen lowered Immunic from a “hold” rating to a “sell” rating in a research report on Sunday, April 19th. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Immunic presently has an average rating of “Buy” and a consensus price target of $47.57.

Immunic Price Performance

NASDAQ IMUX traded up $0.83 during mid-day trading on Friday, hitting $13.13. The company’s stock had a trading volume of 93,566 shares, compared to its average volume of 327,193. Immunic has a 52-week low of $5.06 and a 52-week high of $15.10. The stock’s fifty day simple moving average is $11.40 and its two-hundred day simple moving average is $8.75. The firm has a market capitalization of $178.83 million, a P/E ratio of -2.35 and a beta of 1.20.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.37). On average, equities analysts forecast that Immunic will post -4.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunic

Several hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd purchased a new position in shares of Immunic during the 4th quarter valued at approximately $120,000. Virtu Financial LLC bought a new stake in shares of Immunic in the third quarter worth $99,000. Two Sigma Investments LP acquired a new stake in Immunic in the third quarter valued at $52,000. Qube Research & Technologies Ltd bought a new position in Immunic during the 3rd quarter valued at $29,000. Finally, Bank of America Corp DE grew its holdings in Immunic by 80,724.2% during the 1st quarter. Bank of America Corp DE now owns 143,867 shares of the company’s stock worth $160,000 after acquiring an additional 143,689 shares in the last quarter. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.